QuidelOrtho Corporation (QDEL)

NASDAQ: QDEL · Real-Time Price · USD
27.08
+1.89 (7.50%)
At close: Aug 13, 2025, 4:00 PM
26.50
-0.58 (-2.14%)
After-hours: Aug 13, 2025, 5:08 PM EDT
7.50%
Market Cap 1.84B
Revenue (ttm) 2.74B
Net Income (ttm) -466.40M
Shares Out 67.90M
EPS (ttm) -6.92
PE Ratio n/a
Forward PE 9.84
Dividend n/a
Ex-Dividend Date n/a
Volume 1,544,550
Open 25.43
Previous Close 25.19
Day's Range 25.09 - 27.13
52-Week Range 22.05 - 49.45
Beta -0.03
Analysts Buy
Price Target 42.57 (+57.2%)
Earnings Date Aug 5, 2025

About QDEL

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease,... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 1979
Employees 6,600
Stock Exchange NASDAQ
Ticker Symbol QDEL
Full Company Profile

Financial Performance

In 2024, QuidelOrtho's revenue was $2.78 billion, a decrease of -7.17% compared to the previous year's $3.00 billion. Losses were -$2.05 billion, 20216.8% more than in 2023.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for QDEL stock is "Buy." The 12-month stock price target is $42.57, which is an increase of 57.20% from the latest price.

Price Target
$42.57
(57.20% upside)
Analyst Consensus: Buy
Stock Forecasts

News

QuidelOrtho Launches Certified Analyzer Program

Initiative to expand testing access to underserved U.S. communities SAN DIEGO , Aug. 13, 2025 /PRNewswire/ -- QuidelOrtho Corporation has launched a Certified Analyzer Program, an innovative initiativ...

2 hours ago - PRNewsWire

QuidelOrtho Corporation (QDEL) Q2 2025 Earnings Call Transcript

QuidelOrtho Corporation (NASDAQ:QDEL) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Brian J. Blaser - President, CEO & Director Joseph M.

7 days ago - Seeking Alpha

QuidelOrtho Reports Second Quarter 2025 Financial Results

― Labs revenue grew 4% as reported and 5% in constant currency ― ― Adjusted EBITDA margin improved by 330 basis points; Achieved $100 million annualized cost savings from initiatives announced in 2024...

8 days ago - PRNewsWire

QuidelOrtho Recognized with Three Awards in 2025 IMV ServiceTrak™

SAN DIEGO , July 29, 2025 /PRNewswire/ -- QuidelOrtho earned three awards and top rankings in the 2025 IMV ServiceTrak™ Awards, presented at the Association for Diagnostics & Laboratory Medicine, reco...

15 days ago - PRNewsWire

Urgent Need for Early Detection in Drug Overdose Cases Highlighted in New Podcast

Episode 49 of QuidelOrtho Science Bytes explores substance use trends, the limits of Narcan, and the evolving challenges facing emergency departments SAN DIEGO , July 24, 2025 /PRNewswire/ -- In emerg...

20 days ago - PRNewsWire

QuidelOrtho to Report Second Quarter 2025 Financial Results

SAN DIEGO , July 22, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-o...

22 days ago - PRNewsWire

Real Labs, Actual Decisions With Actionable Six Sigma Metrics

QuidelOrtho Announces Featured ADLM Session SAN DIEGO , July 17, 2025 /PRNewswire/ -- How can actionable, Six Sigma insights improve lab performance? In a featured session at the Association for Diagn...

27 days ago - PRNewsWire

QUIDELORTHO AND BÜHLMANN LABORATORIES AG ANNOUNCE AVAILABILITY OF FECAL CALPROTECTIN (FCAL®) TURBO AND FECAL PANCREATIC ELASTASE (FPELA®) TURBO ASSAYS ON VITROS™ SYSTEMS AS A MICROTIP™ PARTNERSHIP ASSAY (MPA)

Gastrointestinal biomarker tests enhance patient diagnosis of IBD and pancreatic insufficiency on leading clinical chemistry platforms SAN DIEGO , July 14, 2025 /PRNewswire/ -- QuidelOrtho Corporation...

4 weeks ago - PRNewsWire

QuidelOrtho Strengthens Leadership Team With Appointments of Senior Vice Presidents for Global Quality and Clinical & Regulatory Affairs

New executives bring deep expertise to elevate quality and accelerate innovation across global operations SAN DIEGO , July 7, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company"...

5 weeks ago - PRNewsWire

QuidelOrtho Announces Strategy to Accelerate Growth in Molecular Diagnostics

―Company Intends to Acquire LEX Diagnostics Upon U.S. FDA Clearance― ―Company Plans to Discontinue Savanna® Platform Development― ―Company Reaffirms Full Year 2025 Financial Guidance ― ―Company to Hos...

2 months ago - PRNewsWire

QuidelOrtho to Participate in Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs ...

2 months ago - Business Wire

QuidelOrtho: Stagnant Growth Means Best To Avoid (Rating Downgrade)

Despite a once promising future, QuidelOrtho Corporation's current prospects are unappealing. I rated QuidelOrtho as a "Buy" in July 2023, but the stock has since declined by ~60% as its growth has st...

3 months ago - Seeking Alpha

QuidelOrtho Corporation (QDEL) Q1 2025 Earnings Call Transcript

QuidelOrtho Corporation (NASDAQ:QDEL) Q1 2025 Results Conference Call May 7, 2025 5:00 PM ET Company Participants Juliet Cunningham - Vice President, Investor Relations Brian Blaser - President and C...

3 months ago - Seeking Alpha

QuidelOrtho Reports First Quarter 2025 Financial Results

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care setting...

3 months ago - Business Wire

QuidelOrtho to Report First Quarter 2025 Financial Results

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company”) or (“QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care setti...

4 months ago - Business Wire

QuidelOrtho® Introduces Results Manager™ System

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”) announces the availability of the QuidelOrtho® Results Manager™ System, an informatics solution designed to address t...

5 months ago - Business Wire

QuidelOrtho to Participate in the 46th Annual Raymond James Institutional Investor Conference

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (NASDAQ: QDEL) (“QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs ...

6 months ago - Business Wire

QuidelOrtho Corporation (QDEL) Q4 2024 Earnings Call Transcript

QuidelOrtho Corporation (NASDAQ:QDEL) Q4 2024 Results Conference Call February 12, 2025 5:00 PM ET Company Participants Juliet Cunningham - Vice President, Investor Relations Brian Blaser - President...

6 months ago - Seeking Alpha

QuidelOrtho Reports Fourth Quarter and Full-Year 2024 Financial Results

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care setting...

6 months ago - Business Wire

QuidelOrtho Announces Preliminary Unaudited Revenue for Fourth Quarter 2024

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care setting...

7 months ago - Business Wire

Kuehn Law Encourages Investors of QuidelOrtho Corporation to Contact Law Firm

NEW YORK , Jan. 7, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of QuidelOrtho Corporation (NASDAQ: QDEL)  breached ...

7 months ago - PRNewsWire

QuidelOrtho to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs ...

8 months ago - Business Wire

QuidelOrtho Announces Appointment of Two Independent Directors to its Board

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care setting...

8 months ago - Business Wire

Carlyle Sells QuidelOrtho Shares, Analyst Sees Overhang Lifted

On Tuesday, QuidelOrtho Corporation QDEL priced the previously announced underwritten secondary offering by Carlyle Partners VI Cayman Holdings of 8.26 million shares.

9 months ago - Benzinga

Powell Industries Reports Weak Sales, Joins Target, QuidelOrtho And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday.

Other symbols: TGTPOWL
9 months ago - Benzinga